secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001178913-25-002559
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion reports new preclinical data: up to 97% cancer cell inhibition, first evidence against KRAS Q61H mutation
--------------------------------------------------------------------------------

- SIL204 achieved up to 97% inhibition in pancreatic cancer cells with KRAS Q61H mutation (previously untested).
- Dose-dependent inhibition of up to 94% in pancreatic cancer cells with KRAS G12D mutation at nanomolar concentrations.
- Nearly 90% inhibition in colorectal cancer cells with KRAS G12D mutation, extending efficacy beyond pancreatic cancer.
- Data covers three major KRAS-driven cancers: pancreatic, colorectal, and lung; on track for Phase 2/3 trial in Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002559/0001178913-25-002559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002559/zk2533519.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-002559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer